Press Release: Annual financial statements 2013: -2-

aap Implantate AG / Annual financial statements 2013: aap lays cornerstone to become the leading EU based trauma company 2013: Sales EUR 40 million (+10%); EBITDA EUR 7.0 million (+15%) . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

aap Implantate AG (XETRA: AAQ.DE), delivered on its financial and strategic goals, setting the stage for long term growth. We have made progress in 2013, especially in the growth of the Trauma business, further development of the technologies silver coating and magnesium alloys, the divestment of our non-core anti-adhesion product Adcon(R) and our orthopedic reconstructive implant business (hip, knee and shoulder products) as well as with the divestment of our contract manufacturing business (EMCM B.V.) early 2014.

2013 - Results and Milestones

In EUR million 2013 2012 Change Sales 40.0 36.4 +10 % EBITDA (normalized)* 7.0 6.1 +15 % EBIT (normalized)* 3.8 3.0 +27 % Cash-EBT 3.5 2.1 +67 % Economic profit[1] 0.4 -1.6 >100 %

* EBITDA/EBIT without one-time effects from share disposal and costs involved (2013) as well as write-ups on intangible assets (2012)

[1] Economic profit = (ROCE-WACC) x capital employed / Return on Capital Employed (ROCE) is a ratio that indicates the efficiency and profitability of a company's capital investments. Thereby is the EBIT divided by the total capital minus short term liabilities and cash / Weighted Average Cost of Capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets.

In 2013 we achieved important goals which are summarized as follows:

-- Sales revenue increase of 10% to EUR 40 million

-- Normalized EBITDA growth of 15% from EUR 6.1 million to EUR 7.0 million

-- First time realization of an economic profit of EUR 0.4 million

-- Trauma sales (incl. LOQTEQ(R)) increased from EUR 6.3 million to EUR 9.6 million

-- Further market penetration with our LOQTEQ(R)-system and a sales boost of EUR 2.0 million to EUR 5.0 million (+150 %)

-- Net debt reduced from EUR 4.3 million to EUR 3.0 million (incl. discontinued operations)

-- Signed a development and supply agreement for a PMMA bone cement and mixing system with a global orthopedic company

-- Signed a license agreement for the anti adhesive product Adcon(R) for EUR 1.6 million

-- Spin off of recon business into a joint venture (aap Joints GmbH); sell off of 67% of the shares for EUR 3 million

In 2013, aap increased sales from EUR 36.4 million to EUR 40 million (+10%). The stated goal of a 10% sales increase for 2013 which was published early in 2013 was successfully accomplished. The sales increase was supported especially by the Trauma business, which increased from EUR 6.3 million to EUR 9.6 million but also from the signing of multiple license agreements. The development of our innovative LOQTEQ(R) portfolio was particularly positive with a sales increase of 150% to EUR 5.0 million.

The EBITDA increased by 4% from EUR 7.1 million to EUR 7.4 million and the EBIT decreased from EUR 3.2 million to EUR -2.1 million. Both financial years contain one-time effects; a normalized EBITDA and EBIT (without one-time effects) make a comparison easier. The one-time effects in the EBITDA 2013 are a positive effect in connection with the divestment of the shares in aap Joints GmbH (EUR 0.6 million) as well as the incurred costs in connection with the divestment of the contract manufacturing business (EMCM B.V.; EUR 0.2 million). In 2012, an appreciation of assets amounting EUR 1.0 million, was reported. The EBIT was affected by extraordinary depreciations (2013: Goodwill EUR 4 million, capitalized development costs EUR 2.3 million; 2012: capitalized development costs EUR 0.8 million) which are associated with the divestment of EMCM as well as the change in the principles for the capitalization of development costs in the Biomaterials business. Without one-time effects, the normalized EBITDA amount to EUR 7.0 million (previous year: EUR 6.1 million; +15%) and the normalized EBIT to EUR 3.8 million (previous year: 3.0 million; +27%). The stated goal at the beginning of 2013 for an increased EBITDA growth of 15% and a corresponding profitable growth was therefore also accomplished.

Evaluation of the 2013 Management Agenda

Customers Goals Results Goal of the 2013 Management Agenda of the 2013 Management Agenda achieved Grow Trauma sales to >EUR 10 million (+60%), including Trauma total sales: EUR 9.6 million Yes LOQTEQ(R) sales >EUR 5 million (+140%) LOQTEQ(R) sales: EUR 5.0 million Appoint distributors in seven of the nine BRICS- and Russia was added, contracts signed now with five out Partly, SMIT-countries (2012: four) of nine countries distributors in 5 out of 9 countries Expand LOQTEQ(R) portfolio to twelve plates (2012: CE for 9 plating systems in 2013 Partly six) Supply allograft scCO(2) products to bone banks in Signed contracts for Belgium, Netherlands, Austria Yes, even at least four EU countries, preferably including Germany and Turkey; Germany in application though permission for Germany is pending

Innovation Goals Results Goal of the 2013 Management Agenda of the 2013 Management Agenda achieved Freshness index of at least 20% (industry benchmark) Freshness index of 21.5% as proportion of product Yes sales was achieved Develop new instrument sets for LOQTEQ(R) Improvements made for various instruments Yes Initiation of new Trauma portfolio "Polyaxial" Initiation of development of in-house polyaxial locking Yes system Preparation of application file for first silver coated Good progress made, including a related technology Yes trauma product patent granted in the USA

Finance Goals Results Goal of the 2013 Management Agenda of the 2013 Management Agenda achieved Profitable growth: sales +10% Sales +10% and EBITDA +15% Yes and EBITDA +15% Working capital ratio to sales Working capital ratio 2013: 2.4 Yes > 2.2 Positive Economic Profit (ROCE For the first time achieved a positive economic profit Yes > WACC) of EUR 0.4 million DCR < 2 and ICR > 10 (Basis: DCR 0.5 and ICR 32.9 Yes operative EBITDA)

Organization/IT Goals Results Goal of the 2013 Management Agenda of the 2013 Management Agenda achieved Further optimization of supply chain by implementing Evaluation of the ERP systems and of the functionalities Partly more ERP functionality with consultants; concrete actions planed for 2015 Study feasibility of outsourcing predefined products Completed and on going Yes Divestment/ out licensing non-core products and IP Sold the Recon business and outlicensing of the non-core Yes product Adcon(R); License agreement for BonOs Inject(R) (cement used in the spinal region)

Outlook 2014

The ongoing implementation of aaps focus strategy will be the cornerstone in the financial year 2014. We want to generate strong sales growth with a focus on the Trauma business and the LOQTEQ(R) product family in particular.

After der divestment of the contract manufacturing business in February 2014, the management board has set itself the following, updated goals for 2014:

-- Sales growth with an increase of 22% to EUR 35 million (previous year: EUR 28.6 million) for the continued operations Trauma and Bone cement and mixing systems

-- EBITDA between EUR 5 million and EUR 6 million (growth of 0% to 20%)

-- Growing Trauma sales to > EUR 15 million (>50%)

-- Appointing a distributor in the USA and further expansion of the distribution network beyond BRICS- and SMIT-countries

-- Accelerate the development of silver-coated Trauma products (MORE TO FOLLOW) Dow Jones Newswires

   March 31, 2014 08:20 ET (12:20 GMT)- - 08 20 AM EDT 03-31-14

-2 of 4- 31 Mar 2014 12:20:00 UTC  Press Release: Annual financial statements 2013: -2-
-- Expanding the LOQTEQ(R) portfolio; striving for >90% indication coverage

-- Sustain Freshness index of >20%

In the first quarter of 2014 we expect sales between EUR 6.8 million and EURSHYSHY 7.0 million and an EBITDA between 0 and EUR 0.5 million. The contract manufacturing business (EMCM B.V.) will be included only until the end of February 2014.

The goal is to increase our Trauma activities through a combination of organic growth and additional acquisitions. In order to further accelerate the transformation of aap into an international Trauma company, we have initiated studies to consider the position of aap Biomaterials GmbH (Business with bone cements and mixing systems) as part of our business portfolio.

The full consolidated financial statements of aap Implantate AG will be published latest by April 30, 2014. The reason for this delayed publication lies with the divestment of our subsidiary EMCM B.V. by the end of February and the resulting extensive accounting and reporting requirements as well as the translation of the approved consolidated financial statements from German into English.

The supervisory board already approved the consolidated and individual financial statements of aap Implantate AG as of December 31, 2013. Also, both financial statements received the unqualified audit opinion by our independent auditor. Due to the growing number of non-German speaking investors and other stakeholders as well as the regulations of the German stock exchange which require corporate publications both in German and English, we have decided to delay the publication until the end of April. This press release in German and English is based on the consolidated financial statements as of December 31, 2013, which is approved and issued with an unqualified opinion by the independent auditor. It contains next to the consolidated balance sheet, the consolidated statement of comprehensive income and the consolidated cash flow statement and the consolidated schedule of changes in equity an overview of selected financial figures.

_________________________________________________________________

aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG

aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company's products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company's products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap's stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement

This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact: aap Implantate AG, Marc Heydrich, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany

Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: m.heydrich@aap.de

____________________

Selected Figures in EUR million

Sales and result 1.1. - 31.12.2013 1.1. - 31.12.2012 Change Sales 40.0 36.4 10% EBITDA (normalized)[1] 7.0 6.1 15% EBITDA-margin (sales) 18% 17% EBIT (normalized)[1] 3.8 3.0 27% EBIT margin (sales) 10% 8% Cash-EBT[2] 3.5 2.1 67% Net result -3 2 -208% Cash flow and investments 1.1. - 31.12.2013 1.1. - 31.12.2012 Change Operative Cash-Flow 3.5 7.1 -51% Investing activities in intangible assets 2.1 3.0 -30% Investing activities in tangible assets 3.6 0.9 300% Total investing activities 5.7 3.9 46% Value development 31.12.2013[3] 31.12.2012 Change Intangible assets 14.5 39.4 -63% Tangible assets 5.9 5.1 16% Working capital 13.9 14.9 -7% Working capital Ratio (sales)[4] 2.9 2.4 18% Non-current assets 22.4 44.9 -50% Current assets 42.8 23.7 81% Capital structure 31.12.2013 31.12.2012 Change Total assets 65.3 68.6 -5% Shareholders equity 48.5 50.9 -5% Equity ratio 74% 74% Debt coverage ratio (DCR) 0.5 0.8 -38% Interest coverage ratio (ICR) 32.9 11.8 179% Shares[5] 31.12.2013 31.12.2012 Change Total amount of shares (million pieces) 30.7 30.7 0% Share price (closing) (EUR) 2.15 1.34 60% Market Capitalization (million EUR) 65.9 41.1 61% Share price (average) (EUR) 1.45 1.02 42% Share price (high) (EUR) 2.22 1.45 53% Share price (low) (EUR) 1.22 0.7 74% Average Volume/day (pieces) 30,426 29,029 5% Employees group 31.12.20133 31.12.2012 Change Employees (Headcount) 290 261 11% Employees (FTE) 274 247 11%

[1] EBITDA/EBIT without one-time effects from share disposal and costs involved (2013) as well as appreciation on intangible assets (2012)

[2] EBT excluding capitalized development work and depreciation thereof

[3] Figures considering intangible assets and debts of the discontinued operations that will be assumed by the buyer

[4] Sales for the last four quarters

[5] Closing prices XETRA

Consolidated Balance Sheet according to IFRS as of December 31, 2013

31.12.2013 31.12.2012 Assets TEUR TEUR Non-current assets 22,394 44,921 Intangible assets 14,502 39,403 Goodwill 1,568 12,490 Capitalized Services 12,074 21,858 Intangible assets 860 5,055 Tangible assets 5,906 5,107 Trade receivables 170 0 At-Equity financial assets 1,554 55 Financial assets 238 356 Deferred taxes 24 0 Current assets 42,843 23,669 Inventories 9,429 13,943 Trade receivable 6,866 4,226 Receivables from service contracts 281 0 Other financial assets 1,405 1,331 Other assets 348 471 Cash and bank balances 1,580 3,698 Assets classified as held for sale 22,934 0 Total assets 65,237 68,590

31.12.2013 31.12.2012 Liabilities and shareholders' equity TEUR TEUR Shareholdersequity 48,451 50,866 Subscribed Capital 30,670 30,670 Capital reserve 18,768 18,611 Revenue reserve 228 228 Other Reserves 490 608 (MORE TO FOLLOW) Dow Jones Newswires

   March 31, 2014 08:20 ET (12:20 GMT)- - 08 20 AM EDT 03-31-14

-3 of 4- 31 Mar 2014 12:20:00 UTC  Press Release: Annual financial statements 2013: -3-
Consolidated Balance Sheet Profit/Loss -1,705 749 Non-current liabilities (above 1 year) 3,115 4,706 Financial liabilities 2,144 2,000 Other financial liabilities 190 388 Deferred taxes 0 2,090 Provisions 27 27 Other liabilities 754 201 Current liabilities (up to 1 year) 13,671 13,018 Financial liabilities 2,568 4,486 Advance payment 0 1,125 Gross amount due to customers for contract work 25 0 Trade accounts payable 2,853 3,259 Due to partners 0 1,057 Other financial liabilities 1,491 1,753 Provisions 230 205 Other liabilities 558 1,133 Liabilities due to discontinued business 419 0 Liabilities directly associated with assets classified as held for sale 5,527 0 Total Liabilities and Shareholders' equity 65,237 68,590

Consolidated Statement of Comprehensive Income according to IFRS for the period January 1 to December 31, 2013

2013 2012 2013 2012 2013 2012 2013 2012 Continued Discontinued operations operations Consolidation Group Total TEUR TEUR TEUR TEUR TEUR TEUR TEUR TEUR Sales 28,573 26,965 12,317 10,375 -901 -926 39,989 36,414 Changes in inventories of finished goods and work in progress -704 3 -265 176 0 0 -969 179 Other own work capitalized 1,742 2,416 279 328 0 0 2,021 2,744 Other operating income 4,164 2,007 380 1,526 -268 -268 4,276 3,265 Cost of purchased materials and services -8,282 -8,724 -4,565 -2,978 897 926 -11,950 -10,776 Personnel expenses -11,295 -10,682 -3,293 -2,811 0 0 -14,588 -13,493 Depreciation of tangible assets and intangible assets -4,362 -1,959 -5,107 -1,952 0 0 -9,469 -3,911 Other operating expenses -9,063 -8,837 -2,580 -2,641 272 268 -11,371 -11,210 Other taxes -54 0 0 0 0 0 -54 0 Operating income 719 1,189 -2,834 2,023 0 0 -2,115 3,212 Financial result -179 -427 -2 -64 0 0 -181 -491 Income / Expense from joint ventures and associates 21 -1 0 0 0 0 21 -1 Result before income taxes (and minority interest) 561 761 -2,836 1,959 0 0 -2,275 2,720 Income tax 131 185 -310 -495 0 -179 -310 Result before minority interest 692 946 -3,146 1,464 0 0 -2,454 2,410 Minority interest 0 0 0 0 0 0 0 0 Result after tax 692 946 -3,146 1,464 0 0 -2,454 2,410 Valuation of available-for-sale assets* -117 0 0 0 0 0 -117 0 Income tax effect 0 0 0 0 0 0 0 0 Total comprehensive income 575 946 -3,146 1,464 0 0 -2,571 2,410 Net income per share (basic) in EUR 0.02 0.03 -0.10 0.05 - - -0.08 0.08 Net income per share (diluted) in EUR 0.02 0.03 -0.10 0.05 - - -0.08 0.08 Weighted average shares outstanding (basic) in units 30,670 30,670 30,670 30,670 - - 30,670 30,670 Weighted average shares outstanding (diluted) in units 31,011 30,670 31,011 30,670 - - 31,011 30,670 *Might be reclassified in future periods in other income in consolidated statement of comprehensive income

Consolidated Cash Flow Statement according to IFRS

01.01. - 01.01. - 31.12.2013 31.12.2012 TEUR TEUR Net income (after tax) from continued operations 692 946 Net income (after tax) from discontinued operations -3,146 1,464 Net income (after tax) -2,454 2,410 Expenses from share based payments 158 208 Depreciation and impairment loss of fixed assets/current assets 9,469 3,911 Appreciation of fixed assets 0 -999 Changes in deferred taxes -121 -86 Changes in provisions 95 11 Gain/Loss from retirement of subsidiary -782 -945 Gains/loss from retirement of fixed assets 679 11 Share of net profit/loss of associates -21 1 Changes in inventories, other receivables and other assets -4,289 1,353 Changes in other liabilities 813 1,213 Cash flow from operating activities 3,547 7,088 Additions to intangible and tangible assets -5,719 -3,902 Incoming payments from investing activities 24 9 Incoming payments from subsidiary minus incurred cash 0 -2 Incoming payments from retirement of shares from subsidiaries minus incurred cash 3,475 -25 Cash flow from investing activities -2,220 -3,920 Outgoing payments from raising ownership shares in subsidiaries 0 -101 Inflow from financial liabilities 2,262 2,963 Redemption of shareholder loan -750 -2,395 Redemption of financial liabilities -3,815 -2,001 Redemption of finance lease -217 -88 Dividend payments 0 0 Cash flow from financing activities -2,520 -1,622 Decrease / Increase in cash & cash equivalents -1,193 1,546 Cash & cash equivalents at beginning of period 3,698 2,152 Cash & cash equivalents at end of period 2,505 3,698

Consolidated Schedule of Changes in Equity

Revenue reserves Non-cash changes in equity Other Balance Shares Subscribed Capital Legal revenue Revaluation Available-for-sale Sheet of the Minority capital reserve reserves reserves reserve assets Total result group interests Total

01.01.2012 30,670 40,422 42 186 608 608 -23,575 48,353 -3 48,350 Increase in shares 0 0 0 0 0 0 0 0 0 Stock options 0 208 0 0 0 0 0 208 208 Settlement of capital reserve with balance sheet loss 0 -21,914 0 0 0 0 21,914 0 0 Raising ownership shares in subsidiaries 0 -105 0 0 0 0 0 -105 3 -102 Income of the group 2012 0 0 0 0 0 0 2,410 2,410 2,410 31.12.2012 30,670 18,611 42 186 608 0 608 749 50,866 0 50,866 (MORE TO FOLLOW) Dow Jones Newswires

   March 31, 2014 08:20 ET (12:20 GMT)- - 08 20 AM EDT 03-31-14

-4 of 4- 31 Mar 2014 12:20:00 UTC  Press Release: Annual financial statements 2013: -4-
Increase in shares 0 0 0 0 0 0 0 0 0 Stock options 0 157 0 0 0 0 0 157 157 Valuation of available-for-sale assets 0 0 0 0 -118 -118 0 -118 -118 Raising ownership shares in subsidiaries 0 0 0 0 0 0 0 0 0 Income of the group 2013 0 0 0 0 0 0 -2,454 -2,454 -2,454 31.12.2013 30,670 18,768 42 186 490 0 490 -1,705 48,451 0 48,451

aap_KJA2013_ENG: http://hugin.info/130121/R/1772897/604091.pdf

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: aap Implantate AG via Globenewswire

HUG#1772897

--- End of Message ---

aap Implantate AG

Lorenzweg 5 Berlin Germany

WKN: 506660;ISIN: DE0005066609;

Listed: Freiverkehr in Börse Stuttgart,

Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,

Freiverkehr in Börse Berlin,

Freiverkehr in Börse Düsseldorf,

Freiverkehr in Bayerische Börse München,

Freiverkehr in Niedersächsische Börse zu Hannover,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse;

www.aap.de (END) Dow Jones Newswires

   March 31, 2014 08:20 ET (12:20 GMT)- - 08 20 AM EDT 03-31-14